Extended Data Fig. 9|. MS177 represses MLL-r leukemia growth in multiple animal models established by human cell line xenograft or PDX.

(a) Violin plots showing complete blood counting (CBC) of white blood cells (WBC), red blood cells (RBC), neutrophils and lymphocytes, as well as hematocrit or hemoglobin, in C57BL/6 mice treated with either vehicle (n=3) or MS177 (with a dose of 100 mg/kg, BID, 6 days/week, i.p. [n=3]; or 200 mg/kg, BID, 3 days/week, i.p. [n=2]) on day 5, 10, 15 and 21. The boundaries of the violin plots indicate the 25th and 75th percentiles.

(b) The body weight change of C57BL/6 mice treated with either vehicle (n=3; mean ± SD) or MS177 (100 mg/kg, BID, 6 days/week, i.p. [n=3; mean ± SD]; or 200 mg/kg, BID, 3 days/week, i.p. [n=2; mean ± SD]) over a course of 21 days.

(c-d) Flow cytometry-based analysis for the expression of human-specific cell surface antigens (~93% as hCD45+/hCD33+, c) and GFP (from a cell-labeling construct, d) among the splenic cells harvested from leukemic mice, established by intravenous (i.v.) injection of an MLL-r AML PDX line carrying the stably expressed luciferase/GFP reporter (PDX # 68555-Luc).

(e-f) Body weight change of NSG-SGM3 mice bearing the MLL-r AML PDX tumors, xenografted either intravenously (e) or subcutaneously (s.c.; f), as measured from the starting time point of treatment with the indicated dose of vehicle or MS177 over a course of 21 days. Mean ± SD.

(g) Body weight change of NSG mice bearing the subcutaneous RS4;11 cell xenografts, as measured from the starting point of treatment with the indicated dose of vehicle or MS177 over a course of 21 days. Mean ± SD.

(h) Immunoblotting for the indicated proteins using a collection of the s.c. xenografted EOL-1 tumors, which were freshly isolated from NSG mice treated with vehicle or 200 mg/kg of MS177 (BID per day) for a total of 5 days.

Numerical source data and unprocessed blots are available as source data.